Clinical manufacturing batch released, first site activated
Filed with ASX · · 2 pages · English
Summary by 6ix AI
The first clinical trial site has been activated at The Alfred in Melbourne, allowing patient screening and enrollment to commence. The company anticipates dosing its first patient later this month, which is a critical step in demonstrating the advantages of its off-the-shelf cell therapy platform.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Arovella Therapeutics Limited on 6ix
Earlier from Arovella Therapeutics
- Arovella Appoints Acting CEO
- Board Refresh and CEO Resignation
- CLDN18.2 CAR iNKT Cell Preclinical Data Update
- Half Year Report and Appendix 4D
- ALA's ind for ALA-101 accepted by the U.S.FDA
Later from Arovella Therapeutics
- The path to first patient dosing
- Second Clinical Batch Released for Immediate Patient Use
- Arovella receives R&D tax rebate of $4.03 million
- Quarterly Activities/Appendix 4C Cash Flow Report
- First Patient Dosed with ALA-101
Follow Arovella Therapeutics into a list and get an email when it puts out news.
Follow Arovella Therapeutics